Boris E. Reisberg
Northwestern University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Boris E. Reisberg.
Progress in Cardiovascular Diseases | 1979
Boris E. Reisberg
As long as the illicit use of heroin and other drugs continues in our society, infective endocarditis will remain a significant medical problem in the drug-using population. The majority of infections are produced by S. aureus, and the tricuspid valve is most commonly involved. Addicts, unlike the general population, may also develop endocarditis with a variety of gram-negative bacilli and have a higher incidence of fungal infection. The outcome of each individual infection is dependent on the prompt recognition of the underlying valvular infection and the institution of antimicrobial therapy. Infection of the tricuspid valve has a much more favorable prognosis than does infection of the aortic or mitral valves. Fungal endocarditis, and frequently gram-negative bacillary endocarditis, require valvular surgery to effect a cure.
International Journal of Antimicrobial Agents | 1998
Lance R. Peterson; Michael Postelnick; T.L Pozdol; Boris E. Reisberg; Gary A. Noskin
We evaluated a strategy designed to improve useful activity of ciprofloxacin against Pseudomonas aeruginosa. Following changes in antimicrobial agent use made by the institutional Pharmacy and Therapeutic Drug Committee, monthly drug usage and microbial susceptibility records from June 1992 through October 1995 were reviewed. From July 1992 through October 1992 (Period 1), ciprofloxacin and ofloxacin usage represented 95 and 5% of total quinolone doses; from December 1992 to March 1993 (Period 2), ciprofloxacin represented 19%; from July 1993 to October 1993 (Period 3), ciprofloxacin usage represented 85%; from July 1994 to October 1994 (Period 4), ciprofloxacin represented 95%; and from July 1995 to October 1995 (Period 5), ciprofloxacin and ofloxacin respectively represented 98 and 2% of total quinolone doses. Comparison of the anti-pseudomonal activity of the two fluoroquinolones to ofloxacin use, ciprofloxacin use and total quinolone use during the entire observational period showed the highest (negative) correlation with ofloxacin use versus ofloxacin activity (y = -15.04x + 1367.99, r2 = 0.06, w = 0.126). Increased use of quinolones plus a change to primarily ofloxacin usage appeared to adversely affect the activity of both ofloxacin and ciprofloxacin against P. aeruginosa.
Diagnostic Microbiology and Infectious Disease | 1996
Gary A. Noskin; Jenny K. Lee; Donna M. Hacek; Michael Postelnick; Boris E. Reisberg; Valentina Stosor; Sigmund A. Weitzman; Lance R. Peterson
Invasive infections due to Candida krusei are often observed in immunocompromised patients who have received prior therapy with fluconazole, although infection has also occurred in patients in the absence of this antifungal agent. From August 25 through September 19, 1995, we identified four patients with C. krusei fungemia on our hematology/oncology unit. Molecular typing of all the isolates was performed by restriction endonuclease analysis of genomic DNA using HinfI. A total of 7 patients found to be colonized or infected with C. krusei were matched with 14 controls. There was no difference between the cases and controls with respect to underlying disease, duration of hospitalization, or neutropenia. The numbers of days of hyperalimentation, corticosteroids, and antibiotics were similar between both groups. The mean number of antibiotics was greater in the cases versus controls (5.0 versus 2.5; p = .003). There was no difference with respect to total dose or duration of fluconazole administration. Molecular typing of the isolates revealed that four had identical DNA banding patterns, plus another two that differed by one band and were considered related. Three historical strains were unrelated. In conclusion, this report demonstrates that molecular typing can be used to define clonality and, thereby, support increased infection control practices to eliminate such outbreaks when evidence of clonal spread is present.
Morbidity and Mortality Weekly Report | 1997
Boris E. Reisberg; Rebecca Wurtz; P. Diaz; B. Francis; P. Zakowski; S. Fannin; D. Sesline; S. Waterman; R. Sanderson; T. McChesney; R. Boddie; M. Levy; G. Miller; G. Herrera
American Journal of Clinical Pathology | 1999
Donna M. Hacek; Terra Suriano; Gary A. Noskin; Julie Kruszynski; Boris E. Reisberg; Lance R. Peterson
Journal of Clinical Microbiology | 1996
U R Bodnar; Gary A. Noskin; Terra Suriano; Isabell Cooper; Boris E. Reisberg; Lance R. Peterson
JAMA | 1973
Grant O. Westenfelder; Philip Y. Paterson; Boris E. Reisberg; Gloria M. Carlson
American Journal of Clinical Pathology | 1998
Mondira Bhattacharya; Stephen E. Dietrich; Laura Mosher; Farida Siddiqui; Boris E. Reisberg; William S. Paul; John R. Warren
JAMA | 1997
Boris E. Reisberg; Rebecca Wurtz
Journal of Antimicrobial Chemotherapy | 1982
Frank R. Venezio; Grant O. Westenfelder; Francis V. Cook; James E. Williams; Mary M. Carruthers; Boris E. Reisberg; Janet Emmerman; John P. Phair